HIV-1 protease-IN-4

HIV-1 protease-IN-4

• UNSPSC Description: HIV-1 protease-IN-4 (Compound II-22) is a potent HIV-1 protease inhibitor. HIV-1 protease-IN-4 is a proagent of atazanavir. HIV-1 protease-IN-4 as a proagent that delivers the parent 1 to rat plasma with a 5-fold higher AUC and 67-fold higher C24 when compared to oral administration of the parent agent[1].
• Target Antigen: HIV
• Type: Reference compound
• Related Pathways: Anti-infection
• Applications: COVID-19-anti-virus
• Field of Research: Infection
• Assay Protocol: https://www.medchemexpress.com/hiv-1-protease-in-4.html
• Solubility: 10 mM in DMSO
• Smiles: COC(N[C@@H](C(C)(C)C)C(N[C@@H](CC1=CC=CC=C1)[C@@H](OC(OC(OC([C@@H](N(C)C)C(C)C)=O)C)=O)CN(NC([C@H](C(C)(C)C)NC(OC)=O)=O)CC2=CC=C(C=C2)C3=CC=CC=N3)=O)=O
• Molecular Weight: 920.10
• References & Citations: [1]Subbaiah MAM, et al. (Carbonyl)oxyalkyl linker-based amino acid prodrugs of the HIV-1 protease inhibitor atazanavir that enhance oral bioavailability and plasma trough concentration. Eur J Med Chem. 2020 Dec 1;207:112749.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported